Archive: Company News
Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer
Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the appointment of Dr. Rachel Abbott as Chief Executive Officer (CEO). Rachel steps up from her current role as Pan Cancer T’s Chief Scientific Officer (CSO), succeeding Katrien Reynders-Frederix who has served as CEO since the company’s inception.
Positive Interim Data of BellaSeno’s Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
— Data presented at RACS 91st Annual Scientific Congress 2023
— Initial findings demonstrate that BellaSeno’s resorbable implants are safe, well tolerated and lead to natural tissue growth
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced positive interim results from two clinical trials of its products sponsored by its Australian subsidiary, BellaSeno Pty. The results were presented at the 91st Annual Scientific Congress 2023 of the Royal Australasian College of Surgeons (RACS).
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
– OMN6 demonstrates safety and tolerability at clinically significant dose levels
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced positive top-line results from the Phase I clinical trial of its lead compound OMN6, an anti-infective with a completely novel mechanism of action. All endpoints were met: No severe or serious adverse events (SEs/SAEs) were observed at any dose level in the study while clinically meaningful levels of OMN6 were achieved in the blood and complete clearance of the drug was demonstrated, allowing for multiple daily infusions as is common with anti-infective treatments.
ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
– Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Michael A. Curran, PhD, has been appointed Chairman of the Company´s Scientific Advisory Board. In addition to Dr. Curran, Taha Merghoub, PhD, Ulf Petrausch, MD, and Paul Bowness, MD, PhD, currently serve as Scientific Advisors to ImmunOs.